Annual fee revenue distribution: • 30% to cover EMEA staff costs • 30% is paid to the rapporteur and co-rapporteur for the medicinal product concerned for the production of annual safety reports and other supervisory tasks • 30% attributed to special activities and projects agreed by the Management Board, in consultation with the scientific committees (i. e. pharmacovigilance meetings, availability of veterinary medicines, crisis management and other post-marketing projects) • up to 10% for sampling and testing costs for centrally authorised medicines under an agreement with the Council of Europe ’ s European Department for the Quality of Medicines and the network of Official Medicines Control Laboratories